Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_50eb752940fa4aa36756a6bc9f6f3504 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-02 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 |
filingDate |
2019-08-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c05ea9f25963a01a0a3187582487f577 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_23c2267553cb4ea6fb55489c58751fba http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_918ccad648c55578793af068c4a42946 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_de20133b9620035f41c44ee3ce5c5ee2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7986168ef55a8581d7e2906c6406b2c2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f181befe69032797c2f58c4d90d822d4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d1b2acc0a2f286d91c27fbbc584050e3 |
publicationDate |
2020-02-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-2020048337-A1 |
titleOfInvention |
Pharmaceutical composition for safe and effective treatment of knee and/or hip pain |
abstract |
A pharmaceutical composition and a method for treating knee and/or hip pain in a patient non-responsive or intolerant to standard analgesic therapy are disclosed. A pharmaceutical composition and a method for reducing risk for developing an arthropathy in a subject receiving an anti-NGF antibody for treatment of knee and/or hip pain are disclosed. Also provided herein are methods for monitoring safety of a treatment of knee and/or hip pain involving administration of an anti-NGF antibody. In certain aspects, the subject has osteoarthritis of the knee and/or hip and the anti-NGF antibody is fasinumab. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023092052-A1 |
priorityDate |
2018-08-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |